Joint Pain Injections Market Analysis

Joint Pain Injections Market Analysis

To get key market trends

  Download Free Sample

Based on injection type, the joint pain injections market is segmented into hyaluronic acid injections, corticosteroid injections, and platelet rich plasma injections. The hyaluronic acid injections segment held 64.8% revenue share in 2023 and is projected to notable expansion at 7.9% CAGR during the forecast period.
 

• The aging population and the development of technologically advanced products are expected to drive market growth. The growing preference for minimally invasive procedures, along with the quick clinical results, is projected to propel market expansion in the coming years.
   
• Hyaluronic acid injections are employed in treating knee osteoarthritis and help promote knee joint function. This therapeutic approach is known as viscosupplementation, with around 90% of viscosupplement prescriptions indicated for knee osteoarthritis.
   
• According to the Osteoarthritis Research Society International (OARSI), corticosteroids and hyaluronic acid injections are commonly used to manage osteoarthritis, although viscosupplementation is comparatively more effective than corticosteroids. These factors are anticipated to drive market growth.
   

Based on joint type, the joint pain injections market is classified into knee, shoulder & elbow, ankle & hip, and other joint types. The knee segment is anticipated to witness substantial growth to reach USD 2.7 billion during the analysis timeframe.
 

• This high market share is largely attributed to the significant prevalence of knee-related conditions. Osteoarthritis (OA) is a chronic, degenerative joint condition characterized by gradual damage to articular cartilage and underlying bone.
   
• OA is a common rheumatic ailment that affects the majority of older adults and is accompanied by pain and joint stiffness. Additionally, joint damage leads to progressive functional limitations. According to a 2020 Lancet study, the global prevalence of knee OA was around 16.0%, with an incidence rate of 203 per 10,000 individuals.
   
• As part of the overall treatment, physical therapy, rehabilitation, non-steroidal anti-inflammatory drugs, and viscosupplementation (VS) with hyaluronic acid are commonly used. Thus, the high prevalence of knee conditions and the use of joint pain injections to treat these conditions are projected to drive market growth.
   

Based on end user, the joint pain injections market is bifurcated into hospitals, clinics, and other end users. The hospitals segment dominated the market with 56.3% revenue share in 2023 and will foresee a similar trend during the forecast timeframe.
 

• High adoption of advanced therapeutics that provide improved outcomes will drive patient preference for hospitals. Increased admissions for various orthopedic disorders, along with the availability of trained professionals, bolster the demand for joint pain injections and hip replacement devices in these facilities.
   
• Additionally, hospitals provide continuous monitoring post-surgery, design exercise regimens to restore strength, work closely with patients, and offer physical therapies. Therefore, patient preference for well-equipped facilities will support revenue growth in this segment in the near future.
   
• The rising patient inflow has further increased the product adoption rate.
   

North America region market held the largest share of 47.4% in 2023 and is set to witness substantial growth in the coming years.
 

• This large revenue share is primarily due to the increasing prevalence of arthritis and other bone-related issues, coupled with the rapid adoption of new products.
   
• The rising prevalence of orthopedic conditions in the geriatric population, an increasing number of road accidents and sports injuries, continuous therapeutic innovations, and growing demand for joint pain products are some of the key factors driving market growth in the region.
   

The U.S. joint pain injections market is poised to grow at 7.3% of CAGR to reach USD 3.1 billion by the end of the forecast period.
 

• According to the U.S. Bone & Joint Initiative, in 2021, musculoskeletal diseases affected over 50% of individuals aged 18 and above in the U.S., including nearly three out of four people aged 65 and older.
   
• This high prevalence of musculoskeletal disorders, including joint pain, drives demand for effective treatments, such as joint pain injections. With a growing aging population, the incidence of joint-related issues is expected to increase, further fueling the need for pain management solutions.
   

China joint pain injections market anticipated to witness growth in coming years.
 

• The expanding geriatric population and the rise in chronic disease incidence in China are key drivers for market progression. Increasing healthcare expenditure in developing countries, along with surging investments in R&D to introduce advanced joint pain injections, supports business growth.
   

India is expected to experience growth at significant rate in global joint pain injections market.
 

• Increasing awareness about joint health and pain management options, including joint pain injections, is leading to higher adoption rates among patients suffering from arthritis and other musculoskeletal disorders. Government-run health programs and awareness campaigns are key in spreading information and encouraging timely treatment.
   
• Rising disposable incomes and improved healthcare infrastructure in India are enabling better access to advanced pain management solutions, including joint pain injections. This economic growth also allows healthcare providers to adopt and offer innovative therapies.
   
• The entry of new market players and expansion of local manufacturing facilities are helping to reduce the cost of joint pain injections, making them more affordable and accessible across various regions. This market accessibility is expected to support the long-term growth of the market in India.